CDCA

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, Irbesartan, Safety, Jay Traver, CMA, Therapy, SG, European, Heart Protection Study, Disease, Research, CSL Vifor, GAAP, Risk, Webcast, FDA, Proteinuria, Patient, R, Commercial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, UPCR, Growth, Income tax, Total, EGFR, Table, HCU, Bank statement, SAN, Prescription, New Drug Application, EMA, Shanda, International, CDCA, CTX, Caregiver, Food, Education, Video game, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Vaccine, Bank, IgA nephropathy, FSGS

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2022 financial results and provided a corporate update.

Key Points: 
  • Net product sales of $52 million for the fourth quarter of 2022; $201 million for the full year 2022
    SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2022 financial results and provided a corporate update.
  • Research and development (R&D) expenses for the fourth quarter of 2022 were $60.2 million, compared to $62.2 million for the same period in 2021.
  • In the fourth quarter of 2022, enrollment completed in the sixth and final cohort of the ongoing Phase 1/2 COMPOSE Study.
  • ET to discuss company updates as well as fourth quarter and full year 2022 financial results.

Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration

Retrieved on: 
Wednesday, January 18, 2023
Health, Infectious Diseases, COVID-19, Research, Science, Pharmaceutical, Biotechnology, Emricasan, Peace and Collaborative Development Network, Immunity, CDCA, Safety, Videophilia (and Other Viral Syndromes), Organization, Immune system, Patient, HIV disease progression rates, Caspase, Commercialization, Pharmaceutical industry, COVID19

Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.

Key Points: 
  • Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.
  • Caspase molecules help build immunity to pathogens, but can also have detrimental effects on the immune system.
  • The scientists at Amerimmune had the idea that a stronger and prolonged caspase activity can cause the poor outcomes seen in some patients with COVID-19.
  • Histogen Inc. filed for arbitration to terminate the Collaborative Development and Commercialization Agreement (CDCA) between Amerimmune and Histogen Inc.

Travere Therapeutics Provides Corporate Update and 2023 Outlook

Retrieved on: 
Monday, January 9, 2023
Disease, Immunoglobulin A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Union, European Medicines Agency, Therapy, Conditional, CDCA, CTX, Kidney, Safety, FDA, Heart Protection Study, CMA, NDA, Focal segmental glomerulosclerosis, FSGS, Food, Patient, Russell Travers, HCU, EMA, PDUFA, Pharmaceutical industry, IgA nephropathy

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2022 to be approximately $52 million. For the fiscal year 2022, the Company expects total revenue of $212 million, inclusive of approximately $201 million in net product sales and approximately $11 million in licensing and collaboration revenue. The Company ended 2022 with approximately $450 million in cash, cash equivalents and marketable securities. The Company also provided a general update on its development programs, including anticipated milestones for 2023.

Key Points: 
  • The Company also provided a general update on its development programs, including anticipated milestones for 2023.
  • “This is a very exciting year for Travere and the rare disease community, with the first potential approvals from our development pipeline of therapies targeting rare diseases with significant unmet needs.
  • Pending data supportive of approval, the Company anticipates submitting a supplemental NDA for traditional approval for FSGS in the second half of 2023.
  • The Company expects to announce complete full year 2022 financial results and provide a corporate update in late February.

Verde launches P4G shareholder earnings strategy after securing Banco do Brasil financing backed by future sales contracts

Retrieved on: 
Monday, January 24, 2022
City, B3, Federal, P4G, IPO, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Board of directors, CDCA, Cornerstone, Organic, World, Federation, Rio Verde, Goiás, GLOBE, Hospital, CDI, Health, Â, Central Bank of Brazil, Company, Agriculture, Contract, TSX, Federal government of Brazil, SELIC, BB, Board, Security (finance), Pension fund, Bank, Pharmaceutical industry, Farmer, Growth

Previously, financing could only be secured by invoice discounting or guaranteed by capital goods, now Verde's future sales contracts are accepted as debt collateral.

Key Points: 
  • Previously, financing could only be secured by invoice discounting or guaranteed by capital goods, now Verde's future sales contracts are accepted as debt collateral.
  • Banco do Brasil S.A. (BB) has granted to Verde a line of credit through Agribusiness Certificate of Credit Rights (CDCA, from Certificado de Direitos Creditrios do Agronegcio).
  • The guarantee of the operations are future sales contract with Verde.
  • P4G is being engineered in detail so that it can make the most of the Company's potential earnings without compromising its accelerated growth strategy.

Sertainty Selected to Present for the Palmetto Tech Bridge Pitch Jam Prize Challenge at the 2021 CDCA Defense Summit

Retrieved on: 
Thursday, December 9, 2021
Risk, Technology, MLS, Data, Privacy, Organization, CDCA, Intelligence, Intellectual property, Theft, Association, Risk management, Medical device

NASHVILLE, Tenn., Dec. 9, 2021 /PRNewswire-PRWeb/ -- Sertainty is one of three premier organizations that have been chosen to present at the 2021 Palmetto Tech Bridge Pitch Jam Prize Challenge.

Key Points: 
  • NASHVILLE, Tenn., Dec. 9, 2021 /PRNewswire-PRWeb/ -- Sertainty is one of three premier organizations that have been chosen to present at the 2021 Palmetto Tech Bridge Pitch Jam Prize Challenge.
  • This challenge is part of the 14th annual Charleston Defense Contractors Association Defense Summit, one of the largest defense events on the East Coast.
  • "The opportunity to present our groundbreaking end-to-end data privacy technology before so many esteemed industry leaders is an honor."
  • Sertainty is also a finalist for the grand prize of the Pitch Jam Challenge in the category of MLS.

WesternU College of Dental Medicine receives $1 million gift from WREB for scholarships

Retrieved on: 
Saturday, August 21, 2021
Dentist, Commission on Dental Competency Assessments, Texas, University, Cole, ADEX, CDM, Interim, Commission, Student, Intention, District, Dental hygienist, Western Regional Examining Board, Al-Ghad International Health Sciences Colleges, Board, Licensure, Dental education throughout the world, Assistant, Dean (education), Time, Outline of health sciences, DMD, CDCA, Columbia University College of Dental Medicine, Integration, Faculty, Organization, Idaho State University, Idaho, School, Humour, Health care, Professional, DDS, Curriculum, Dentistry

POMONA, Calif., Aug. 20, 2021 /PRNewswire-PRWeb/ --Western University of Health Sciences College of Dental Medicine (CDM) received a $1 million gift from the Western Regional Examining Board (WREB) to fund scholarships and carry on WREB's legacy of helping students.

Key Points: 
  • POMONA, Calif., Aug. 20, 2021 /PRNewswire-PRWeb/ --Western University of Health Sciences College of Dental Medicine (CDM) received a $1 million gift from the Western Regional Examining Board (WREB) to fund scholarships and carry on WREB's legacy of helping students.
  • "We want to make a difference as best we can in dental students' lives to help ease the financial burden of their dental education."
  • WREB identified WesternU and Texas A&M College of Dentistry as the recipients of gifts to create endowed scholarships to support dental students and dental hygiene students.
  • Dean Friedrichsen credits the WesternU faculty and staff with deepening the productive relationship between WREB and the College.